Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 317 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Anticoagulation Clear all
Completed No phase listed Observational Accepts healthy volunteers

Rotational Thromboelastometry (ROTEM) TRUE-NATEM Reference Value Validation in Liver Transplantation

NCT04282889
View directory record Official record
Conditions
Coagulation in Liver Transplantation
Interventions
Not listed
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 3, 2026, 5:11 AM EDT
Withdrawn Phase 1 Interventional

Bivalirudin vs Heparin in ECMO Patients

NCT03707418
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication
Interventions
Heparin Sodium, Bivalirudin Injection [Angiomax]
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Sep 3, 2026, 5:11 AM EDT
Terminated Phase 4 Interventional Results available

Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism

NCT04558125
View directory record Official record
Conditions
Pulmonary Embolism, COVID
Interventions
TNKase, Placebo, Enoxaparin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 3, 2026, 5:11 AM EDT
Terminated Not applicable Interventional Results available

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

NCT02928497
View directory record Official record
Conditions
Stroke
Interventions
WATCHMAN LAAC Device Implant, Single Antiplatelet Therapy or No Therapy (Control)
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
71
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 3, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

NCT04401293
View directory record Official record
Conditions
Sars-CoV2, COVID
Interventions
Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 3, 2026, 5:11 AM EDT
Terminated Phase 3 Interventional

Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial

NCT02448550
View directory record Official record
Conditions
Percutaneous Coronary Intervention
Interventions
Bivalirudin, Unfractionated heparin
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Sep 3, 2026, 5:11 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin

NCT02206100
View directory record Official record
Conditions
Healthy
Interventions
PER977, Placebo, enoxaparin
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 3, 2026, 5:11 AM EDT
Recruiting Phase 3 Interventional

Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial

NCT07006675
View directory record Official record
Conditions
Tibial Fractures, Pain
Interventions
600 mg Ibuprofen
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Cambridge, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 3, 2026, 5:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Stroke Feasibility Study

NCT01997905
View directory record Official record
Conditions
Atrial Fibrillation, AFib
Interventions
AtriClip LAA Exclusion Device
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
St. Helena, California • Miami, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 3, 2026, 5:11 AM EDT
Completed No phase listed Observational

Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

NCT03214172
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 3, 2026, 5:11 AM EDT
Not yet recruiting Phase 4 Interventional

Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease

NCT07713875
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Spine Metastasis
Interventions
Apixaban
Drug
Lead sponsor
James Bayley
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Pittburgh, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 3, 2026, 5:11 AM EDT
Completed No phase listed Observational

Anticoagulation in Emergency General Surgery

NCT04216394
View directory record Official record
Conditions
Emergency General Surgery
Interventions
Emergency general surgery
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
4 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 3, 2026, 5:11 AM EDT
Completed No phase listed Observational

Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed

NCT05548777
View directory record Official record
Conditions
Anticoagulant-related Major Bleed
Interventions
Andexanet alfa, 4F-PCC
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
5,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Agoura Hills, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 3, 2026, 5:11 AM EDT
Recruiting Phase 3 Interventional

SAfety of Regional Citrate Anticoagulation (SARCA Study)

NCT05339139
View directory record Official record
Conditions
Acute Kidney Injury, ESRD
Interventions
Dialysis
Combination Product
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Orlando, Florida • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 3, 2026, 5:11 AM EDT
Terminated Phase 3 Interventional Results available

Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism

NCT00423683
View directory record Official record
Conditions
Cancer, Thromboembolism
Interventions
Arixtra alone, Arixtra + filter
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Sep 3, 2026, 5:11 AM EDT
Not listed Not applicable Interventional

Warfarin Patient Self-management Implementation in the US Healthcare System

NCT04766216
View directory record Official record
Conditions
Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases
Interventions
Patient self-management, Usual care provided by anticoagulation providers
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Loma Linda, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 3, 2026, 5:11 AM EDT
Completed No phase listed Observational

Multi-Center Human Alert Trial to Prevent DVT and PE

NCT00409136
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
Interventions
Human Alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Long Beach, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2009 · Synced Sep 3, 2026, 5:11 AM EDT
Not yet recruiting Phase 4 Interventional

Second Line Endovascular Treatment in Acute DVT

NCT06486181
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Thrombolysis/Thrombectomy
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 3, 2026, 5:11 AM EDT
Completed Not applicable Interventional Results available

Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)

NCT00634907
View directory record Official record
Conditions
Venous Thromboembolism, Bleeding
Interventions
Pharmacogenetic-based warfarin dosing, Usual care warfarin dosing
Genetic · Other
Lead sponsor
Gwen McMillin
Other
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 3, 2026, 5:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Pharmacodynamic Study of Rivaroxaban

NCT01743898
View directory record Official record
Conditions
Blood Clot
Interventions
Rivaroxaban, no anticoagulation
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 89 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2014 · Synced Sep 3, 2026, 5:11 AM EDT
Recruiting Phase 2 Interventional

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

NCT07175428
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
REGN7508, REGN9933, Apixaban
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
43
States / cities
Dothan, Alabama • Fairhope, Alabama • Covina, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 3, 2026, 5:11 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

NCT04077463
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lazertinib, Amivantamab, Carboplatin, Pemetrexed
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 3, 2026, 5:11 AM EDT
Recruiting Not applicable Interventional

VCOM Pain Free Research Collaborative

NCT06533345
View directory record Official record
Conditions
Chronic Pain
Interventions
Behavior Change Coaching, Nutrition, Autonomic Recalibration, Dry Needling, Osteopathic Manipulative Treatment, Counseling Psychology, Multiple Treatments
Behavioral · Other · Procedure
Lead sponsor
Edward Via Virginia College of Osteopathic Medicine
Other
Eligibility
21 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 3, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

NCT01042704
View directory record Official record
Conditions
Myeloma
Interventions
Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
Drug · Other
Lead sponsor
Robert Redner, MD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
22
States / cities
Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 3, 2026, 5:11 AM EDT